Terms: = Kidney tumors AND FLCN, BHD, 201163, ENSG00000154803, MGC23445, MGC17998, FLCL AND Treatment
29 results:
1. Hereditary Renal Cancer Syndromes.
Yanus GA; Kuligina ES; Imyanitov EN
Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
[TBL] [Abstract] [Full Text] [Related]
2. [Expert consensus on the diagnosis and management of Birt-Hogg-Dubé syndrome].
; ; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Sep; 46(9):897-908. PubMed ID: 37670643
[TBL] [Abstract] [Full Text] [Related]
3. Germline- and Somatic-Inactivating flcn Variants in Parathyroid Cancer and Atypical Parathyroid tumors.
Jha S; Welch J; Tora R; Lack J; Warner A; Del Rivero J; Sadowski SM; Nilubol N; Schmidt LS; Linehan WM; Weinstein LS; Simonds WF; Agarwal SK
J Clin Endocrinol Metab; 2023 Sep; 108(10):2686-2698. PubMed ID: 36935552
[TBL] [Abstract] [Full Text] [Related]
4. treatment Strategies for Hereditary kidney Cancer: Current Recommendations and Updates.
Singh S; Chaurasia A; Gopal N; Malayeri A; Ball MW
Discov Med; 2022; 34(173):205-220. PubMed ID: 36602871
[TBL] [Abstract] [Full Text] [Related]
5. Birt-Hogg-Dubé syndrome with rare unclassified renal cell carcinoma: A case report.
Ren S; Luo C; Wang Y; Wei Y; Ou Y; Yuan J; Li X; Wang J; Lv Q; Yang B; Fan S; Zhou F; Chen Z; Nie Y; Wang D
Medicine (Baltimore); 2021 Dec; 100(51):e28380. PubMed ID: 34941164
[TBL] [Abstract] [Full Text] [Related]
6. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
[TBL] [Abstract] [Full Text] [Related]
7. Familial kidney Cancer: Implications of New Syndromes and Molecular Insights.
Carlo MI; Hakimi AA; Stewart GD; Bratslavsky G; Brugarolas J; Chen YB; Linehan WM; Maher ER; Merino MJ; Offit K; Reuter VE; Shuch B; Coleman JA
Eur Urol; 2019 Dec; 76(6):754-764. PubMed ID: 31326218
[TBL] [Abstract] [Full Text] [Related]
8. Percutaneous thermal ablation for renal cell carcinoma in patients with Birt-Hogg-Dubé syndrome.
Matsui Y; Hiraki T; Gobara H; Iguchi T; Tomita K; Uka M; Araki M; Nasu Y; Furuya M; Kanazawa S
Diagn Interv Imaging; 2019 Nov; 100(11):671-677. PubMed ID: 31302073
[TBL] [Abstract] [Full Text] [Related]
9. Pathology of Birt-Hogg-Dubé syndrome: A special reference of pulmonary manifestations in a Japanese population with a comprehensive analysis and review.
Furuya M; Nakatani Y
Pathol Int; 2019 Jan; 69(1):1-12. PubMed ID: 30632664
[TBL] [Abstract] [Full Text] [Related]
10. Renal transplantation in Birt-Hogg-Dubé syndrome: should we?
Coutinho J; de Sa J; Teixeira FC; Santos CR; Chorão RS; Filipe RA; Rocha EF
BMC Nephrol; 2018 Oct; 19(1):267. PubMed ID: 30326848
[TBL] [Abstract] [Full Text] [Related]
11. Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma.
Priolo C; Khabibullin D; Reznik E; Filippakis H; Ogórek B; Kavanagh TR; Nijmeh J; Herbert ZT; Asara JM; Kwiatkowski DJ; Wu CL; Henske EP
Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6274-E6282. PubMed ID: 29891694
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of bladder hydrodistension for decreased bladder capacity induced by intravesical BCG therapy.
Numakura K; Tsuchiya N; Tsuruta H; Akihama S; Saito M; Inoue T; Narita S; Huang M; Satoh S; Habuchi T
Scand J Urol; 2016 Dec; 50(6):429-432. PubMed ID: 27701987
[TBL] [Abstract] [Full Text] [Related]
13. Oncotargets in different renal cancer subtypes.
Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
[TBL] [Abstract] [Full Text] [Related]
14. Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.
Sirintrapun SJ; Geisinger KR; Cimic A; Snow A; Hagenkord J; Monzon F; Legendre BL; Ghazalpour A; Bender RP; Gatalica Z
Medicine (Baltimore); 2014 Oct; 93(15):e81. PubMed ID: 25275525
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cells.
Zhang Q; Si S; Schoen S; Chen J; Jin XB; Wu G
J Exp Clin Cancer Res; 2013 Dec; 32(1):99. PubMed ID: 24305604
[TBL] [Abstract] [Full Text] [Related]
16. [A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Nakamura M; Yao M; Sano F; Sakata R; Tatenuma T; Makiyama K; Nakaigawa N; Kubota Y
Hinyokika Kiyo; 2013 Aug; 59(8):503-6. PubMed ID: 23995526
[TBL] [Abstract] [Full Text] [Related]
17. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (flcn).
Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
[TBL] [Abstract] [Full Text] [Related]
18. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.
Linehan WM
Genome Res; 2012 Nov; 22(11):2089-100. PubMed ID: 23038766
[TBL] [Abstract] [Full Text] [Related]
19. The impact of germline bhd mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.
Boris RS; Benhammou J; Merino M; Pinto PA; Linehan WM; Bratslavsky G
J Urol; 2011 Jun; 185(6):2050-5. PubMed ID: 21496834
[TBL] [Abstract] [Full Text] [Related]
20. [Multiple spontaneous pneumothoraces revealing Birt-Hogg-Dube syndrome].
Van Denhove A; Guillot-Pouget I; Giraud S; Isaac S; Freymond N; Calender A; Pacheco Y; Devouassoux G
Rev Mal Respir; 2011 Mar; 28(3):355-9. PubMed ID: 21482341
[TBL] [Abstract] [Full Text] [Related]
[Next]
